OVERVIEW
The global cardiac marker testing market is expected to hit USD 4.93 billion by 2025, rising over the forecast period at a CAGR of 8.2%. Factors such as the rising prevalence of cardiovascular diseases, the rapidly growing geriatric population, increased funding from public-private organizations for cardiac biomarker testing, and ongoing clinical trials to identify new cardiac biomarkers are driving overall growth.
TABLE OF CONTENT
1 Global Cardiac Marker Testing Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope
2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions
3 Global Cardiac Marker Testing Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography
4 Global Cardiac Marker Testing Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis
5 Global Cardiac Marker Testing Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies
6 Global Cardiac Marker Testing Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes
7 Global Cardiac Marker Testing Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)
8 Global Cardiac Marker Testing Market – By Type Of Marker (Market Size – & million/billion)
8.1 Troponin I and T
8.2 CK-MB
8.3 Myoglobin
8.4 Brain Natriuretic Peptide (BNP)
8.5 C-reactive Protein
8.6 Other
9 Global Cardiac Marker Testing Market – By Application
9.1 Instruments
9.2 Chemiluminescence
9.3 Immunofluorescence
9.4 ELISA
9.5 Immunochromatography
9.6 Reagents and Kits
10 Global Cardiac Marker Testing Market – By Location Of Testing
10.1 Laboratory Testing
10.2 Point-of-care Testing
11 Global Cardiac Marker Testing Market – By Geography (Market Size – & million/billion)
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 U.K
11.3.2 Germany
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia-Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 South Korea
11.4.5 Rest of APAC
11.5 Rest of the World
11.5.1 South America
11.5.2 Middle East
11.5.3 Africa
12 Global Cardiac Marker Testing Market – Entropy
12.1 New product launches
12.2 M&A’s, collaborations, JVs and partnerships
13 Global Cardiac Marker Testing Market Company Profile (Key Players)
13.1 Market Share, Company Revenue, Products, M&A, Developments
13.2 Roche Diagnostics Limited
13.3 Siemens AG
13.4 Danaher Corporation
13.5 Alere Inc.
13.6 LSI Medience Corporation
13.7 Abbott Laboratories
13.8 Randox Laboratories Ltd.
13.9 Guangzhou Wondfo Biotech Co., Ltd.
13.10 Biomérieux SA
13.11 Ortho Clinical Diagnostics
13.12 Company 11 & more
14 Global Cardiac Marker Testing Market – Appendix
14.1 Sources
14.2 Abbreviations